ES2067866T3 - Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion. - Google Patents

Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion.

Info

Publication number
ES2067866T3
ES2067866T3 ES91304840T ES91304840T ES2067866T3 ES 2067866 T3 ES2067866 T3 ES 2067866T3 ES 91304840 T ES91304840 T ES 91304840T ES 91304840 T ES91304840 T ES 91304840T ES 2067866 T3 ES2067866 T3 ES 2067866T3
Authority
ES
Spain
Prior art keywords
hiv
virus type
react
methods
celulas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91304840T
Other languages
English (en)
Inventor
David Da-I Ho
James Edmun Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars-Sinai Medical Center
Louisiana State University
Original Assignee
Cedars-Sinai Medical Center
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/701,129 external-priority patent/US5798251A/en
Application filed by Cedars-Sinai Medical Center, Louisiana State University filed Critical Cedars-Sinai Medical Center
Application granted granted Critical
Publication of ES2067866T3 publication Critical patent/ES2067866T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fluidized-Bed Combustion And Resonant Combustion (AREA)
  • Gasification And Melting Of Waste (AREA)
  • Devices And Processes Conducted In The Presence Of Fluids And Solid Particles (AREA)
  • Crucibles And Fluidized-Bed Furnaces (AREA)

Abstract

LA INVENCION SE REFIERE A INMUNOREACTIVOS QUE NEUTRALIZAN EL VIRUS DE INMUNODEFICIENCIA HUMANA TIPO 1 (HIV-1) AL ENLAZARSE A UN NUEVO EPITOPE CONSERVADO DEL HIV OREACTIVOS PRESENTAN UN AMPLIO EFECTO NEUTRALIZADOR A LA UNION DEL HIV A CELULAS RECEPTORAS Y SON POR LO TANTO UTILES EN LA DETECCION, PREVENCION, MEJORA Y TRATAMIENTO DE LA ENFERMEDAD PRODUCIDA POR EL HIV, PRINCIPALMENTE EL SIDA (SINDROME DE INMUNODEFICIENCIA ADQUIRIDA) Y EL ARC (COMPLEJO RELACIONADO CON EL SIDA). DE MANERA MAS PARTICULAR, LA INVENCION SE REFIERE A NUEVOS ANTICUERPOS MONOCLONALES HUMANOS SELECTIVAMENTE REACTIVOS A UN DETERMINANTE DEPENDIENTE DE LA CONFORMACION CONSERVADA DEL HIV-1 GP120, DERIVADOS DE LOS MISMOS, LINEAS DE CELULAS QUE PRODUCEN ESTOS ANTICUERPOS Y EL USO DE ANTICUERPOS MONOCLONALES Y SUS DERIVADOS PARA LA DETECCION, PREVENCION, MEJORA Y TRATAMIENTO DE LA ENFERMEDAD RELACIONADA CON EL HIV.
ES91304840T 1990-05-29 1991-05-29 Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion. Expired - Lifetime ES2067866T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53085090A 1990-05-29 1990-05-29
US07/701,129 US5798251A (en) 1990-05-29 1991-05-16 Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120

Publications (1)

Publication Number Publication Date
ES2067866T3 true ES2067866T3 (es) 1995-04-01

Family

ID=27063388

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91304840T Expired - Lifetime ES2067866T3 (es) 1990-05-29 1991-05-29 Reactivos inmunologicos que reaccionan con un epitopo constante del virus inmunodeficiente humano del tipo i (vih-1)gp120 y metodos de utilizacion.

Country Status (12)

Country Link
US (2) US6054284A (es)
EP (2) EP0459779B1 (es)
JP (1) JP2792733B2 (es)
AP (1) AP237A (es)
AT (1) ATE115189T1 (es)
AU (2) AU643285B2 (es)
DE (1) DE69105627T2 (es)
DK (1) DK0459779T3 (es)
ES (1) ES2067866T3 (es)
GR (1) GR3015269T3 (es)
OA (1) OA09499A (es)
WO (1) WO1991018928A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
JPH06501260A (ja) * 1990-09-27 1994-02-10 シンテロ　ヴァクシーン　ディベロップメント　ケービー ヒト免疫不全ウィルスに対する中和抗体の誘発とワクチン接種に用いられるペプチド
WO1992007878A1 (en) * 1990-10-26 1992-05-14 The Public Health Research Institute Of The City Of New York, Inc. Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
JPH06510025A (ja) * 1991-06-03 1994-11-10 シンテロ　ヴァクシン　デベロップメント　アクチ　ボラゲット Ｈｉｖ−１に対するｔ細胞活性化の誘導に用いられるペプチド
CA2174532A1 (en) * 1993-10-19 1995-04-27 Carlos F. Barbas Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
EP1141314A2 (en) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
ATE369427T1 (de) 2001-03-22 2007-08-15 Us Health Glykosylierungsresistente cyanovirine und damit verbundene konjugate, zusammensetzungen, nukleinsäuren, vektoren, wirtszellen, herstellungsverfahren sowie verfahren zur verwendung nichtglykosylierter cyanovirine
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US20050014230A1 (en) * 2003-07-16 2005-01-20 Ccl Holding Co., Ltd. Preparation of fully human antibodies
US7572766B2 (en) 2004-06-16 2009-08-11 Affinergy, Inc. IFBMs to promote the specific attachment of target analytes to the surface of orthopedic implants
US8202523B2 (en) * 2005-09-22 2012-06-19 ProSci, Inc. Glycosylated polypeptides produced in yeast mutants and methods of use thereof
WO2010051215A1 (en) * 2008-10-31 2010-05-06 Proteonova, Inc. Methods for making hiv vaccines and related compositions
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59116230A (ja) * 1982-11-29 1984-07-05 ベイロ−・カレツジ・オヴ・メデイスン ウイルス性感染因子に対する免疫応答を生起する抗−イデイオタイプ抗体
US4536479A (en) * 1983-03-22 1985-08-20 E. I. Du Pont De Nemours And Company Use of anti-idiotype antibodies in immunoassays
AU609447B2 (en) * 1987-02-19 1991-05-02 Nissin Shokuhin Kabushiki Kaisha Methods and materials for hiv detection and therapy
US5215913A (en) * 1987-11-30 1993-06-01 Roger Williams General Hospital IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use
WO1989005827A1 (fr) * 1987-12-15 1989-06-29 Nippon Shokubai Kagaku Kogyo Co., Ltd. Compose photodurcissable
WO1989005821A1 (en) * 1987-12-21 1989-06-29 Arch Development Corporation Hiv-related antigens and antibodies
WO1990002568A1 (en) * 1988-09-13 1990-03-22 Chiron Corporation Hiv-1 envelope muteins lacking hypervariable domains
CA2051107A1 (en) * 1989-04-25 1990-10-26 William N. Sun Antibodies specific for cd4-binding domain of hiv
AU6523590A (en) * 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
US5798251A (en) * 1990-05-29 1998-08-25 Cedars-Sinai Medical Center Antibody and antibody derivative immunoreagents reactive with a conserved epitope of Human Immunodeficiency Virus Type 1 (HIV-1) gp 120
AP237A (en) * 1990-05-29 1993-04-29 Cedars Sinai Medical Center Immunoreagents reactive with a conserved epitope of human immunodeficiency virus type 1 (HIV-1) gp120 and methods of use.
CA2044741A1 (en) * 1990-06-18 1991-12-19 Jade Chin Hiv gp120 monoclonal antibodies
GB9013566D0 (en) * 1990-06-18 1990-08-08 Shell Int Research Process for producing gasoline components

Also Published As

Publication number Publication date
US6054284A (en) 2000-04-25
US6190871B1 (en) 2001-02-20
JP2792733B2 (ja) 1998-09-03
OA09499A (en) 1992-11-15
EP0459779A1 (en) 1991-12-04
JPH05500818A (ja) 1993-02-18
AU660574B2 (en) 1995-06-29
EP0459779B1 (en) 1994-12-07
DE69105627D1 (de) 1995-01-19
AP237A (en) 1993-04-29
DE69105627T2 (de) 1995-04-20
WO1991018928A1 (en) 1991-12-12
AU5510794A (en) 1994-04-28
DK0459779T3 (da) 1995-05-29
ATE115189T1 (de) 1994-12-15
AU7803591A (en) 1991-12-05
AU643285B2 (en) 1993-11-11
GR3015269T3 (en) 1995-06-30
EP0614985A1 (en) 1994-09-14
AP9100280A0 (en) 1991-07-31

Similar Documents

Publication Publication Date Title
EP0675904A4 (en) HUMANE NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE VIRUS FROM HUMAN THAT MAKES THE IMMUNE.
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
DE69435126D1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
ES2076142T3 (es) Peptidos para el diagnostico de anticuerpos para htlv-iii, su preparacion y uso.
DK0512112T3 (da) Anti-CD4-antistoffer, som blokerer HIV-inducerede syncytier
DK0589004T3 (da) Fremgangsmåde til bestemmelse af peptider, som hører til immunologisk vigtige epitoper af HCV
ES2139607T3 (es) Anticuerpos monoclonales contra las proteinas e2/ns1 supuestas vhc y procedimientos de utilizacion de estos anticuerpos.
NZ219113A (en) Hiv peptide containing epitope of the env protein
RU94045826A (ru) Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
FI931393A0 (fi) Peptider foer anvaendning vid vaccinering och induktion av neutraliserande motkroppar mot humant immunbristvirus
ES2147195T3 (es) Metodo para la deteccion de anticuerpos en individuos seronegativos.
ATE335835T1 (de) Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen
ES2059577T3 (es) Fragmentos genicos que codifican para las regiones variables de un anticuerpo anti-hiv, anticuerpos anti-hiv quimericos expresados utilizando los mismos y procedimiento para su preparacion.
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
DE69113520D1 (de) Monoklonale Antikörper gegen HIV GP120.
OA09634A (fr) Antigenes de la glycoproteine transmembranaire d'enveloppe d'un retrovirus humain du type HIV-2 antigenes presentant avec eux une parente immunologique
ATE137801T1 (de) Gegen hiv 1 gp48 spezifische antikörper
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
AR001840A1 (es) Composiciones y métodos para detectar y tratar el sindrome de inmunodeficiencia adquirida
DE69112059D1 (de) Monoklonale antikörper gegen gag-protein-vorläufer-p55 von hiv-virus.
ES2059726T3 (es) Anticuerpos monoclonales que reconocen el itsp humano, hibridomas que producen los mismos, y su preparacion y uso.
DK0429587T3 (da) Fremgangsmåde til fremstilling af et regulationsprotein af HIV-1 under anvendelse af den humane cellelinie TH4-7-5

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 459779

Country of ref document: ES